Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of TIGIT-ECD recombinant protein in resisting allogeneic immunological rejection

A recombinant protein, transplant rejection technology, applied in the field of biomedicine, can solve the problem that patients do not achieve the ideal treatment effect and so on

Inactive Publication Date: 2018-12-07
FOURTH MILITARY MEDICAL UNIVERSITY
View PDF3 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, in practical applications, a considerable proportion of patients still do not achieve the desired therapeutic effect, suggesting that more in-depth research is still needed to explore more co-stimulatory molecular regulation mechanisms

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of TIGIT-ECD recombinant protein in resisting allogeneic immunological rejection
  • Application of TIGIT-ECD recombinant protein in resisting allogeneic immunological rejection
  • Application of TIGIT-ECD recombinant protein in resisting allogeneic immunological rejection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0030] In the present invention, bioinformatics is used to analyze human-derived TIGIT sequence firstly, the extracellular region sequence is cloned, inserted into the expression vector pSectag2-Fc, and the eukaryotic expression plasmid is constructed. After conventional gene sequencing, it was confirmed that the gene sequence was correct; the cell culture supernatant was collected after transfection of HEK293T cells, and the TIGIT-ECD recombinant protein was purified by anti-Fc affinity chromatography technology; in macrophage culture in vitro and LPS stimulation model To detect the effect of TIGIT-ECD recombinant protein on the polarization of macrophages; to detect the effect of TIGIT-ECD on the proliferation and differentiation of T cells in the mixed lymphocyte reaction.

[0031] The present invention will be described in detail below in conjunction with the preparation method and biological activity detection of the TIGIT-ECD recombinant protein, which is an explanation o...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an application of a TIGIT-ECD recombinant protein in resisting allogeneic immunological rejection. The amino acid sequence of the recombinant protein TIGIT-ECD is shown as SEQ ID NO:1. The nucleotide sequence coding the recombinant protein TIGIT-ECD is shown as SEQ ID NO:2. The recombinant protein is capable of effectively regulating macrophage polarization by activating a TIGIT-CD155 signal path, and contributes to inducing allogeneic graft tolerance. Therefore, the recombinant protein TIGIT-ECD can serve as a graft rejective reaction inhibitor, and can also be appliedto preparing drugs for preventing and treating the graft rejective reaction.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, in particular to a recombinant protein TIGIT-ECD and its application in anti-allogenic immune rejection. Background technique [0002] For patients with end-stage organ failure, organ transplantation is an important, even the only means of surgical treatment. Since the 1980s, thanks to the popularity of surgical techniques and broad-spectrum immunosuppressive drugs, the field of organ transplantation has developed rapidly, and hematopoietic stem cell transplantation and various solid organ transplantations have become routine operations. More than 90% of the grafts can achieve good functional survival within the first year after surgery, but the long-term effect is always unsatisfactory. The rejection of the body is a problem that all transplant patients need to face for life. The long-term use of immunosuppressive drugs by recipients of organ transplantation directly causes complications su...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K14/705C12N15/12A61K38/17A61P37/06
CPCA61K38/00A61P37/06C07K14/705
Inventor 庄然张圆张栋梁张赟李琦金伯泉
Owner FOURTH MILITARY MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com